FLT1 and pulmonary fibrosis: Nintedanib is an inhibitor targeting multiple tyrosine kinases, including platelet-derived growth factor receptors, fibroblast growth factor receptors, and VEGFR-1, -2, and -3, and it is already approved for the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer38–40.